Kidney Cancer
Casdatifan Shows Promise in Treating Clear Cell Renal Cell Carcinoma
Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Olanzapine May Help Manage AEs From Tyrosine Kinase Inhibitors
Olanzapine may help manage adverse effects from tyrosine kinase inhibitors, though further randomized, placebo-controlled studies are needed to confirm these findings.
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Proactive Onco-Coaching Improves Survival in Metastatic Kidney Cancer
Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic renal cell carcinoma.
Higher Tivozanib Dose Improves Antitumor Activity in Kidney Cancer
Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.
